The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
Projectdetails
Introduction
Diabetes is one of the biggest health concerns globally: 6% of the world’s population already lives with diabetes, and another 35% is at a high risk of developing it.
Importance of Monitoring
Proper management of diabetes starts with consistent and accurate monitoring of glucose levels. Yet, most diagnosed diabetics do not monitor their blood sugar as often as prescribed, because it is painful and inconvenient to do so.
Industry Need for Change
This is clear evidence that the €16+ billion glucose monitors industry needs a change – the current methods are not good enough.
Innovative Solution
We have invented, patented, and productized a new technology category for extracting and analysing blood sugar levels in a completely non-invasive way.
Funding Application
We are applying for the EIC blended finance to further miniaturise, optimise, and clinically prove this technology on a wider scale.
Potential Impact
The financing will turn our breakthrough scientific discovery into an end-user device that can potentially impact over 2 billion people by helping them prevent diabetes onset altogether.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.500.000 |
Totale projectbegroting | € 6.567.443 |
Tijdlijn
Startdatum | 1-2-2022 |
Einddatum | 31-1-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- GLUCOMODICUM OYpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Minimally invasive reliAble Glucose monitoring in Intensive CareGlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Beta-cell recovery to counter diabetesDiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026. | EIC Accelerator | € 2.500.000 | 2023 | Details |
The first universal and price-neutral insulin penGO-Pen ApS aims to refine and scale the UNIPEN, an affordable and refillable insulin injection system, to improve dosing accuracy for over 13 million people with diabetes. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Lassie: The first-ever painless breath analyser for people with diabetes, a breakthrough in blood glucose monitoringLassie breath analyser BOYDSense aims to provide painless, cost-effective, and discreet diabetes monitoring by analyzing breath VOCs for accurate glucose measurement. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Minimally invasive reliAble Glucose monitoring in Intensive Care
GlucoSet aims to develop a novel continuous glucose monitor for ICU patients to improve glucose control, enhance patient outcomes, and achieve CE-mark approval within 25 months.
Beta-cell recovery to counter diabetes
DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.
The first universal and price-neutral insulin pen
GO-Pen ApS aims to refine and scale the UNIPEN, an affordable and refillable insulin injection system, to improve dosing accuracy for over 13 million people with diabetes.
Lassie: The first-ever painless breath analyser for people with diabetes, a breakthrough in blood glucose monitoring
Lassie breath analyser BOYDSense aims to provide painless, cost-effective, and discreet diabetes monitoring by analyzing breath VOCs for accurate glucose measurement.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes managementFAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions. | ERC Proof of... | € 150.000 | 2022 | Details |
GlucoMoveIQHet project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg. | Mkb-innovati... | € 20.000 | 2024 | Details |
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensingGLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications. | EIC Transition | € 2.194.210 | 2022 | Details |
Ontwikkeling van een pijnloos en gebruiksvriendelijk glucose-meetsysteem met micronaaldenHet project ontwikkelt een universele applicator voor micronaalden om een innovatieve glucosesensor voor diabetici effectief en consistent op de huid aan te brengen. | Mkb-innovati... | € 345.543 | 2019 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
Affordable and sustainable self-powered GLUCOSE sensing system for a global FAIR diabetes management
FAIRGLUCOSE aims to develop a low-cost, self-powered glucose sensing system that reduces waste and enhances accessibility for glucose monitoring, especially in low-income regions.
GlucoMoveIQ
Het project ontwikkelt een subcutane glucosemonitor met hoge nauwkeurigheid en een batterijlevensduur van twee jaar voor betere diabeteszorg.
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensing
GLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications.
Ontwikkeling van een pijnloos en gebruiksvriendelijk glucose-meetsysteem met micronaalden
Het project ontwikkelt een universele applicator voor micronaalden om een innovatieve glucosesensor voor diabetici effectief en consistent op de huid aan te brengen.